S194: TECLISTAMAB (TEC) + NIROGACESTAT (NIRO) IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): THE PHASE 1B MAJESTEC-2 STUDY

Fritz Offner(Ghent University Hospital), Jeffrey Matous(Colorado Blood Cancer Institute), Kevin Boyd(Royal Marsden Hospital), Olivier Decaux(Centre Hospitalier Universitaire de Rennes), Deeksha Vishwamitra(Janssen (United States)), Arnob Banerjee(Johnson & Johnson (United States)), Cyrille Touzeau(Centre National de la Recherche Scientifique), Zhuolu Niu, Luciano J. Costa(University of Alabama at Birmingham), Lingling Chen(Shenzhen University), Yue Guo(Janssen (United States)), Jenna D. Goldberg(Centre Hospitalier Universitaire de Nantes), Anne Sophie Michallet(Hôpital Lyon Sud), Julie S. Larsen(Janssen (United States)), Cyrille Hulin(Hôpital Cardiologique du Haut-Lévêque), Sébastien Anguille(Antwerp University Hospital)
HemaSphere
August 1, 2023
10.1097/01.hs9.0000967688.12579.64
Cited by 31

Related Papers

Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study
|The Lancet|2021|1.7k
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.6k
Teclistamab in Relapsed or Refractory Multiple Myeloma
|New England Journal of Medicine|2022|1.2k
Asymmetric T Lymphocyte Division in the Initiation of Adaptive Immune Responses
|Science|2007|852
Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma
|New England Journal of Medicine|2023|719